As per the agreement, PSI will use Solumer technology to develop drug products for SoluBest’s clients.
PSI expects to provide Solumer formulation and clinical trial supply manufacturing to pharmaceutical and biotech companies.
SoluBest said that the patented Solumer approach utilises GRAS polymers to create drug/polymer complexes that result in greatly improved drug solubility and bioavailability.
SoluBest claims that once the formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient.
PSI CEO Mark Mitchnick said that the Solumer technology fits perfectly with their growth strategy of adopting truly value added drug delivery approaches to the portfolio.
"This is a proven technology that is both cost effective and scalable. It will find application with both NCE’s and generics," Mitchnick said.
"We are very excited to be working with SoluBest and are already evaluating the technology for specific projects."